Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

New England Journal of Medicine

Volumn 349, Issue 26, 2003, Pages 2495-2502

  Attal, Michel ^a   Harousseau, Jean Luc ^b   Facon, Thierry ^c   Guilhot, François ^d   Doyen, Chantal ^e   Fuzibet, Jean Gabriel ^f   Monconduit, Mathieu ^g   Hulin, Cyrille ^h   Caillot, Denis ⁱ   Bouabdallah, Reda ^j   Voillat, Laurent ^k   Sotto, Jean Jacques ^l   Grosbois, Bernard ^m   Bataille, Regis ^b  

^a CHU PURPAN   (France)

^b HÔTEL DIEU   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f University of Côte d'Azur   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^l HÔPITAL MICHALLON   (France)

^m SERVICE DE RHUMATOLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MELPHALAN; RECOMBINANT ALPHA INTERFERON; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; ARTICLE; AUTOTRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE STEM CELL TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SINGLE STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0347815503     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa032290     Document Type: Article

References (24)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
2. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879-82.
3. Barlogie B, Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1991;7:71-9.
4. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
6. Fermand J-P, Ravaud P, Katsahian S, et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999;94:396a. abstract.
7. Blade J, Sureda A, Ribera JM, et al. High-dose therapy and autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2001;98:815a. abstract.
8. 2) vs oral melphalan/prednisone: an interim analysis. Blood 2001;98:849a. abstract.
9. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6.
10. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992;79:2827-33.
11. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84:950-6.
12. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
13. Björkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001;38:219-25.
14. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
15. Fermand J-P, Marolleau J-P, Alberti C, et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Blood 2001;98:815a. abstract.
16. Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144-51.
17. Cavo M, Tosi P, Zamagni E, et al. The "Bologna 96" clinical trial of single vs. double autotransplants for previously untreated multiple myeloma patients. Blood 2002; 100:179a. abstract.
18. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myélome. Semin Hematol 2001; 38:226-30.
19. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomid in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
20. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71. [Erratum, N Engl J Med 2000;342:364.]
21. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71. [Erratum, N Engl J Med 2000;342:364.]
22. Richardson P, Jagannath S, Schlossman R, et al. A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma. Blood 2002;100:104a. abstract.
23. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5.
24. Sirohi B, Powles R, Singhal S, et al. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. Bone Marrow Transplant 2002;29:Suppl 2:S12. abstract.